Fresh analysis reveals that patients who stop using popular weight-loss injections like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who end traditional diet and exercise plans.
Research printed in a leading medical journal points out that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Users purchasing such medications must be cognizant of the danger of fast rebound weight gain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment weight in about 18 months.
Analyzing Therapies
The research, which examined dozens of studies involving thousands of patients, contrasted the results of the injectable medications with other pills.
Researchers note that individuals who shed pounds through dieting generally see a slower weight regain—around 0.1 kg a month—after stopping.
Understanding the Quick Rebound
Nutrition scientists suggest the way of the injections accounts for the amplified weight return.
The injections imitate a body's own chemical called GLP-1, which controls appetite.
"Long-term administration of GLP-1 concentrations far above than normal may cause the system to produce less of its endogenous GLP-1, and could reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement leads to appetite is no longer kept in check, making binge eating far more likely."
A Chronic Issue?
The NHS suggest the injections for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians argue that, given the high risk of weight regain, the therapy is often ongoing.
This opinion is echoed by drug manufacturers, who note that the findings "highlight the persistent character of obesity," similar to managing diseases like hypertension.
Patient Experiences
People who have discontinued the medication explain a sudden resurgence of hunger.
"It was like something flipping and you become extremely hungry," described an individual.
The struggle is exacerbated if patients have not developed permanent dietary or behavioural modifications during therapy.
Growing Use
Figures suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with demand remaining high.
- Adoption is more common among women than men.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, experts caution that while these medications are effective agents for shedding pounds, they are not a standalone fix and long-term success relies on ongoing behavioural management.
